Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies

Oct 01 2012

• By Cathy Dombrowski

Related Content

FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs

Oct 15 2012

<em>Belviq</em> Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch

Jun 28 2012

Arena Must Deal With Rat Neoplasms To Move Forward With <i>Lorqess</i>

Sep 20 2010

FDA Issues Complete Response Letter for Arena's Lorcaserin

Oct 24 2010

FDA FENFLURAMINE/REDUX EPIDEMIOLOGICAL ANALYSIS OF HMO RECORDS SUPPORTS FINDINGS OF VALVULOPATHY IN ASYMPTOMATIC PATIENTS REPORTED FROM FIVE SURVEYS

Sep 22 1997

Related Companies

Arena Pharmaceuticals, Inc.

Vivus, Inc.

Pfizer Inc.

Additional Topics

United States Approvals Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window